Cargando…
Interaction between Immunotherapy and Antiangiogenic Therapy for Cancer
Although immunotherapy has led to durable responses in diverse cancers, unfortunately, there has been limited efficacy and clinical response rates due to primary or acquired resistance to immunotherapy. To maximize the potential of immunotherapy, combination therapy with antiangiogenic drugs seems t...
Autores principales: | Furukawa, Koichi, Nagano, Tatsuya, Tachihara, Motoko, Yamamoto, Masatsugu, Nishimura, Yoshihiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7504110/ https://www.ncbi.nlm.nih.gov/pubmed/32859106 http://dx.doi.org/10.3390/molecules25173900 |
Ejemplares similares
-
Possible Biomarkers for Cancer Immunotherapy
por: Otoshi, Takehiro, et al.
Publicado: (2019) -
Immunotherapy in Advanced Non-Small Cell Lung Cancers: Current Status and Updates
por: Suraya, Ratoe, et al.
Publicado: (2022) -
Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy
por: Nagano, Tatsuya, et al.
Publicado: (2018) -
Synergistic interaction of gemcitabine and paclitaxel by modulating acetylation and polymerization of tubulin in non-small cell lung cancer cell lines
por: Effendi, Wiwin Is, et al.
Publicado: (2019) -
Successful Treatment of ROS1-rearranged Lung Cancer Complicated by Hypertrophic Pulmonary Osteoarthropathy with Crizotinib Therapy
por: Katsurada, Naoko, et al.
Publicado: (2019)